JPWO2019241555A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019241555A5 JPWO2019241555A5 JP2020568772A JP2020568772A JPWO2019241555A5 JP WO2019241555 A5 JPWO2019241555 A5 JP WO2019241555A5 JP 2020568772 A JP2020568772 A JP 2020568772A JP 2020568772 A JP2020568772 A JP 2020568772A JP WO2019241555 A5 JPWO2019241555 A5 JP WO2019241555A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- alkyl
- vmat2 inhibitor
- composition
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims description 175
- 125000000217 alkyl group Chemical group 0.000 claims description 173
- 208000020016 psychiatric disease Diseases 0.000 claims description 112
- 238000000034 method Methods 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 60
- 125000000623 heterocyclic group Chemical group 0.000 claims description 59
- 150000004677 hydrates Chemical class 0.000 claims description 58
- 239000012453 solvate Substances 0.000 claims description 58
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 56
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 125000003342 alkenyl group Chemical group 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 31
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims description 31
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 31
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 31
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000004429 atom Chemical group 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- -1 -OH Chemical group 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 206010011703 Cyanosis Diseases 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 108700028369 Alleles Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 206010029216 Nervousness Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 230000004596 appetite loss Effects 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 238000005204 segregation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 45
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024104749A JP2024114905A (ja) | 2018-06-14 | 2024-06-28 | Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684935P | 2018-06-14 | 2018-06-14 | |
| US62/684,935 | 2018-06-14 | ||
| PCT/US2019/037046 WO2019241555A1 (en) | 2018-06-14 | 2019-06-13 | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104749A Division JP2024114905A (ja) | 2018-06-14 | 2024-06-28 | Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528386A JP2021528386A (ja) | 2021-10-21 |
| JPWO2019241555A5 true JPWO2019241555A5 (https=) | 2022-06-16 |
| JP2021528386A5 JP2021528386A5 (https=) | 2022-06-16 |
Family
ID=67263041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568772A Withdrawn JP2021528386A (ja) | 2018-06-14 | 2019-06-13 | Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法 |
| JP2024104749A Pending JP2024114905A (ja) | 2018-06-14 | 2024-06-28 | Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104749A Pending JP2024114905A (ja) | 2018-06-14 | 2024-06-28 | Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP4691560A3 (https=) |
| JP (2) | JP2021528386A (https=) |
| KR (1) | KR20210021006A (https=) |
| CN (1) | CN112638387A (https=) |
| AU (1) | AU2019287524A1 (https=) |
| BR (1) | BR112020024018A2 (https=) |
| CA (1) | CA3100694A1 (https=) |
| EA (1) | EA202092750A1 (https=) |
| IL (1) | IL278758A (https=) |
| JO (1) | JOP20200298A1 (https=) |
| MA (1) | MA52896A (https=) |
| MX (1) | MX2020013004A (https=) |
| PH (1) | PH12020552088A1 (https=) |
| SG (1) | SG11202011544UA (https=) |
| TW (1) | TW202011963A (https=) |
| WO (1) | WO2019241555A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY193767A (en) | 2015-10-30 | 2022-10-27 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| CN108925135B (zh) | 2015-12-23 | 2025-09-19 | 纽罗克里生物科学有限公司 | 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法 |
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| ES3024958T3 (en) | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| EP3784237B1 (en) | 2018-04-25 | 2023-11-01 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| US20250000805A1 (en) * | 2021-10-29 | 2025-01-02 | Neurocrine Biosciences, Inc. | Valbenazine compositions |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| PL2081929T3 (pl) * | 2006-11-08 | 2013-06-28 | Neurocrine Biosciences Inc | Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| WO2010044981A2 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2771539A1 (en) | 2009-08-12 | 2011-02-17 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenzine |
| US8782398B2 (en) | 2012-06-26 | 2014-07-15 | Intel Corporation | Secure user presence detection and authentication |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| NZ760790A (en) | 2014-02-07 | 2022-11-25 | Neurocrine Biosciences Inc | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| WO2015171802A1 (en) | 2014-05-06 | 2015-11-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
| CA2974540C (en) * | 2015-02-06 | 2023-09-26 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| EA036837B1 (ru) | 2015-06-23 | 2020-12-25 | Нейрокрин Байосайенсиз, Инк. | Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств |
| TW202345829A (zh) * | 2016-12-02 | 2023-12-01 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| CN110678181A (zh) | 2017-04-01 | 2020-01-10 | 阿德普蒂奥制药有限公司 | (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途 |
| JP7250692B2 (ja) | 2017-04-01 | 2023-04-03 | アデプティオ ファーマシューティカルズ リミテッド | 運動障害の治療における使用のためのジヒドロテトラベナジン |
| JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| ES3024958T3 (en) * | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
-
2019
- 2019-06-13 MX MX2020013004A patent/MX2020013004A/es unknown
- 2019-06-13 TW TW108120550A patent/TW202011963A/zh unknown
- 2019-06-13 JP JP2020568772A patent/JP2021528386A/ja not_active Withdrawn
- 2019-06-13 SG SG11202011544UA patent/SG11202011544UA/en unknown
- 2019-06-13 WO PCT/US2019/037046 patent/WO2019241555A1/en not_active Ceased
- 2019-06-13 BR BR112020024018-4A patent/BR112020024018A2/pt not_active Application Discontinuation
- 2019-06-13 CA CA3100694A patent/CA3100694A1/en active Pending
- 2019-06-13 MA MA052896A patent/MA52896A/fr unknown
- 2019-06-13 JO JOP/2020/0298A patent/JOP20200298A1/ar unknown
- 2019-06-13 KR KR1020217000734A patent/KR20210021006A/ko not_active Ceased
- 2019-06-13 EA EA202092750A patent/EA202092750A1/ru unknown
- 2019-06-13 EP EP25211485.5A patent/EP4691560A3/en active Pending
- 2019-06-13 AU AU2019287524A patent/AU2019287524A1/en not_active Abandoned
- 2019-06-13 EP EP19739758.1A patent/EP3806856A1/en not_active Withdrawn
- 2019-06-13 CN CN201980039832.5A patent/CN112638387A/zh active Pending
-
2020
- 2020-11-17 IL IL278758A patent/IL278758A/en unknown
- 2020-12-04 PH PH12020552088A patent/PH12020552088A1/en unknown
-
2024
- 2024-06-28 JP JP2024104749A patent/JP2024114905A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021528386A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| TWI354666B (en) | Heterocyclic aspartyl protease inhibitors | |
| JP2818820B2 (ja) | 抗炎症剤としての３−アリール−２−イソオキサゾリン類 | |
| JPWO2019241555A5 (https=) | ||
| JP2006516622A5 (https=) | ||
| US20070105903A1 (en) | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | |
| KR940701383A (ko) | 질소 함유 헤테로사이클릭 화합물의 플루오로알콕시벤질아미노 유도체 | |
| JP2596446B2 (ja) | Ｚ―１―（ｐ―β―ジメチルアミノエトキシフェニル）―１―（ｐ―ヒドロキシフェニル）―２―フェニル―ブド―１―エンの安定な溶媒付加物、その製造法及びそれを含有する薬剤 | |
| JPWO2021030555A5 (https=) | ||
| JPWO2021155470A5 (https=) | ||
| JPWO2019014100A5 (https=) | ||
| JP2006500403A (ja) | キノリルプロピルピペリジン誘導体およびその抗菌性物質としての使用 | |
| EP1484328A1 (fr) | Dérivés de la quinolyl propyl piperidine et leur utilisation en tant qu' agents antimicrobiens | |
| JP2009524691A5 (https=) | ||
| JP3256291B2 (ja) | Ｎ−アルキル−３−フェニル−３−（２−アルキルチオフェノキシ）プロピルアミン類 | |
| CA2503732A1 (fr) | Derives de la quinolyl propyl piperidine et leur utilisation en tant qu'antimicrobiens | |
| JP2007514691A5 (https=) | ||
| JPH07502022A (ja) | トリアゾール抗真菌剤 | |
| TW402601B (en) | Aminocycloalkylpyrrolidinyl-substituted quinolone derivatives having antibacterial effect and pharmaceutical composition containing them | |
| JP2008505107A5 (https=) | ||
| JP2016520635A (ja) | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 | |
| JP2005517634A5 (https=) | ||
| JPH05194491A (ja) | イミダゾリルメチル−ピリジン | |
| HUT74671A (en) | Novel (1-phenyl-1-heterocyclyl) methanol and (1-phenyl-1-heterocyclyl) methylamine derivatives and pharmaceutical compositions containing them |